GOFURTGO Clinical Trial
Early detection of pancreatic cancer is difficult. People usually aren’t aware that they are sick. In many cases, even when the cancer is confined to the pancreas area, it is not possible to operate safely to remove the tumour. An alternative approach is to use modern chemotherapy and radiotherapy treatments. The aim of this treatment is to maximise how long the disease can be controlled, whilst maintaining a good quality of life.
The GOFURTGO Clinical Trial aims to establish the effectiveness of new and complicated radiation techniques combined with new chemotherapy combinations in the treatment of patients who have localised but inoperable pancreatic cancer. People on this trial will be offered initial chemotherapy, followed by a combination of radiotherapy and chemotherapy, and then consolidation chemotherapy. It’s called a sandwiched regime as the radiation/chemotherapy regime is sandwiched between the initial and consolidation chemotherapy treatment.
The trial, opened in July 2005, has recruited 48 patients from Australia and New Zealand and it is currently in follow-up.
Study Chairs
Conjoint Professor David Goldstein
Medical Oncologist, Prince of Wales Hospital, NSW, Australia
Clinical Associate Professor Nigel Spry
Radiation Oncologist, Sir Charles Gairdner Hospital, WA, Australia
Funding
- Sanofi-Aventis Group Pty Limited (Australia)
- NHMRC Clinical Trials Centre (Australia)
- Cancer Council New South Wales
- Cancer Council Western Australia
Schema
